tiprankstipranks
BioXcel Therapeutics announces TRANQUILITY In-Care Phase 3 trial plan
PremiumThe FlyBioXcel Therapeutics announces TRANQUILITY In-Care Phase 3 trial plan
14d ago
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
PremiumPress Releases
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
14d ago
BioXcel Therapeutics announces $25M registered direct offering
PremiumThe Fly
BioXcel Therapeutics announces $25M registered direct offering
1M ago
BioXcel Therapeutics announces European Patent Office grant
PremiumThe FlyBioXcel Therapeutics announces European Patent Office grant
1M ago
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
PremiumPress Releases
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
1M ago
BioXcel Therapeutics price target lowered to $7 from $18 at Canaccord
PremiumThe Fly
BioXcel Therapeutics price target lowered to $7 from $18 at Canaccord
1M ago
BioXcel Therapeutics reports Q4 EPS (76c), consensus (91c)
PremiumThe FlyBioXcel Therapeutics reports Q4 EPS (76c), consensus (91c)
1M ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
PremiumPress Releases
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
1M ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100